ArticleEvidence-based complementary and alternative medicine : eCAM2019
Screening the Best Compatibility of
Article in Evidence-based complementary and alternative medicine : eCAM, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 14 citations in OpenAlex.
- Article
- Albiflorin-Mediated MAP2K1 Targeting and HIF-1 Signaling Inhibition Contribute to the Therapeutic Efficacy in Hyperuricemia-Associated Cognitive Impairment.Human mutation · 2026Article
- Anti-inflammatory Properties of Tongfeng Li'an Granules in an Acute Gouty Arthritis Rat Model.ACS omega · 2024Article
- Plantaginis Semen Ameliorates Hyperuricemia Induced by Potassium Oxonate.International journal of molecular sciences · 2024Article
- Natural Xanthine Oxidase Inhibitor 5-Molecules (Basel, Switzerland) · 2021Article
- Lipidomics study of the therapeutic mechanism of Plantaginis Semen in potassium oxonate-induced hyperuricemia rat.BMC complementary medicine and therapies · 2021Article
- The roles of NLRP3 inflammasome-mediated signaling pathways in hyperuricemic nephropathy.Molecular and cellular biochemistry · 2021Review
- A Purified Biflavonoid Extract FromFrontiers in pharmacology · 2021Article
- Advances in Experimental and Clinical Research of the Gouty Arthritis Treatment with Traditional Chinese Medicine.Evidence-based complementary and alternative medicine : eCAM · 2021Review
- Network Pharmacology-Based Investigation of the Mechanism of Action of Plantaginis Herba in Hyperuricemia Treatment.Evidence-based complementary and alternative medicine : eCAM · 2021Article
- The Efficacy and Mechanism of Chinese Herbal Medicines in Lowering Serum Uric Acid Levels: A Systematic Review.Frontiers in pharmacology · 2020Article
- Tongbixiao Pills Improve Gout by Reducing Uric Acid Levels and Inhibiting Inflammation.Dose-response : a publication of International Hormesis SocietyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesThe
conclusionsIn summary, SMP-3 may be a potential therapeutic agent for the prevention of hyperuricemic and gout.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.